Investors in the psychedelics industry have been scrambling the past couple of weeks to gain access to ATAI Life Sciences’ most recent funding round. This new round, which comes after having raised more than $100 million in past funding, is set to be the last opportunity for investors to participate before the company’s IPO. Labeled…